• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

As The Elevator Operator says, “Going Down?”

My 401k Hurts

Guest
I’m not sure what in the world you guys are saying on this conference call right now, but please shut your yapper. You’re not instilling any confidence towards the investment community this morning. They’re fleeing us like a rat-infested ship and jumping off at any price.